Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835317 | 0.77 | ALDH1A1 (0.31) | — | |
| SCHEMBL11778677 | 0.71 | USP2 (0.39) | USP2TSHRHTTHSD17B10 | |
| SCHEMBL6551498 | 0.70 | ALDH1A1 (0.31) | — | |
| SCHEMBL13370672 | 0.66 | USP2 (0.38) | USP2TSHRHTTHSD17B10 | |
| SCHEMBL5334759 | 0.66 | — | — | |
| SCHEMBL11753158 | 0.64 | USP2 (0.37) | USP2TSHRHTTHSD17B10 | |
| SCHEMBL17161345 | 0.64 | USP2 (0.32) | USP2TSHRHTTHSD17B10 | |
| SCHEMBL14117843 | 0.63 | USP2 (0.36) | USP2TSHRHTTHSD17B10 | |
| SCHEMBL11731346 | 0.62 | USP2 (0.41) | USP2TSHRHTTHSD17B10 | |
| SCHEMBL10335060 | 0.62 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7321068-B2 | Method for producing tricyclodecandialdehyde | BASF AKTIENGESELLSCHAFT (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20070100168-A1 | Method for producing tricyclodecandialdehyde | BASF AKTIENGESELLSCHAFT PATENS, TRADEMARKS AND LICENSES (DE) | 2007-05-03 | — | — | US | disclosed |
| EP-1208070-A4 | DIOLEFIN/HYDROXYARYL CONDENSATES AND CATALYST THEREFOR | BORDEN CHEM INC (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1208070-A1 | DIOLEFIN/HYDROXYARYL CONDENSATES AND CATALYST THEREFOR | BORDEN CHEMICAL, INC. (US) | 2002-05-29 | — | — | EP | disclosed |
| US-6291723-B1 | Diolefin/hydroxyaryl condensates and catalyst therefor | BORDEN CHEMICAL, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2001016064-A1 | DIOLEFIN/HYDROXYARYL CONDENSATES AND CATALYST THEREFOR | BORDEN CHEMICAL, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100168-A1 | Method for producing tricyclodecandialdehyde | HRH1, HRH2, HRH4 | USP2 1472/4885TSHR 3052/4885HTT 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.